CN Patent

CN110314154A — 左旋普萘洛尔在制备治疗血管病变药物中的应用

Assigned to Wuhan Hengxinyuan Pharmaceutical Co Ltd · Expires 2019-10-11 · 7y expired

What this patent protects

本发明提供了左旋普萘洛尔在制备治疗血管病变药物中的应用。在治疗血管病变，尤其是在血管瘤的治疗中，左旋普萘洛尔的治疗效果要优于消旋普萘洛尔及右旋普萘洛尔，为临床上对血管瘤或婴幼儿血管瘤的治疗提供了很好的前景。

USPTO Abstract

本发明提供了左旋普萘洛尔在制备治疗血管病变药物中的应用。在治疗血管病变，尤其是在血管瘤的治疗中，左旋普萘洛尔的治疗效果要优于消旋普萘洛尔及右旋普萘洛尔，为临床上对血管瘤或婴幼儿血管瘤的治疗提供了很好的前景。

Drugs covered by this patent

Patent Metadata

Patent number
CN110314154A
Jurisdiction
CN
Classification
—
Expires
2019-10-11
Drug substance claim
No
Drug product claim
No
Assignee
Wuhan Hengxinyuan Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.